window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1');

About Novigenix

Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox®, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix’s technology is based on a new generation of predictive gene expression profiles of circulating blood cells and concentration profile of tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer.

Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test

By |2024-06-17T20:43:09+02:0014 October 2019|Communiqué de presse, News Novigenix|

Test to measure response to radiopharmaceutical therapy LAUSANNE, SWITZERLAND - 07:00 CET, October 14, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology.

Novigenix Strengthens Board with Appointment of Francois Martelet, M.D. Non-Executive Director

By |2024-06-17T20:45:20+02:0018 June 2019|Communiqué de presse, News Novigenix|

LAUSANNE, SWITZERLAND - 07:00 CET, June 18, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Francois Martelet, M.D. to its Board of Directors as a non-executive director. Dr. Martelet has over 25 years’ experience at both corporate and operational

Novigenix Appoints Dr. Jan Groen as CEO to Lead Expansion to Multi-Product Cancer Diagnostic Platform Company

By |2024-06-17T20:48:34+02:0013 May 2019|Communiqué de presse, News Novigenix|

ImmunoTranscriptomic platform combines identification of immune cell mRNA signatures with AI for early cancer detection LAUSANNE, SWITZERLAND - 07:00 CET, May 13, 2019 - Novigenix SA, a leading ImmunoTranscriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Dr. Jan Groen to the position of Chief

Novigenix nomme Jan Groen au poste de CEO pour conduire la transition de la société vers une plateforme technologique de diagnostic du cancer et de médecine de précision

By |2024-06-17T20:48:23+02:0013 May 2019|Communiqué de presse, News Novigenix|

La plateforme ImmunoTranscriptomic combine l'identification des signatures d'ARNm de cellules immunitaires avec l'IA pour la détection précoce du cancer LAUSANNE, SUISSE - 7h00, CET, 13 mai 2019 - Novigenix SA, une société pionnière en ImmunoTranscriptomics qui développe et commercialise des produits pour la détection précoce du cancer et la médecine de précision a annoncé

L’équipe #Novigenix se réjouit de vous accueillir jusqu’à dimanche sur son stand #52: information…

By |2018-12-19T18:49:25+02:0019 December 2018|Linkedin post|

L’équipe #Novigenix se réjouit de vous accueillir jusqu’à dimanche sur son stand #52: information autour de la détection du cancer, quiz, “putt contre la prévention” ainsi qu’échanges divers avec la souriante équipe #Novigenix. Au plaisir de vous y retrouver! Here we go. The Novigenix team is present until Sunday at the Planète Santé Show: information…

Go to Top